3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
5
Phase EARLY_PHASE1
1
Phase 2/3
1
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Carcinosarcoma
1
Endometrial Neoplasms
1
Cystadenocarcinoma, Serous
1
Interventions
Megestrol Acetate
4
Letrozole
4
Paclitaxel
3
Medroxyprogesterone Acetate
3
Carboplatin
3
Gonadotropin-Releasing Hormone
2
Cisplatin
2
spartalizumab
1
sintilimab
1
ricin A-GnRH conjugate
1
olaparib
1
niraparib
1
navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid
1
durvalumab
1
atezolizumab
1
Tablets
1
Progestins
1
Progesterone
1
Observation
1
LHRH, Ac-Nal(1)-Cpa(2)-Trp(3)-Arg(6)-Ala(10)-
1
Drug Therapy
1
Cyproterone acetate, ethinyl estradiol drug combination
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Endometrial Neoplasms
×
niraparib
×
Clear all
NCT04159155
2025-08-12
CAN-STAMP
University Health Network, Toronto
Phase 2/3
Terminated
11 enrolled